ArticleResearch in pharmaceutical sciences2025
Albumin conjugated with WQPDTAHHWATL and GRFLTGGTGRLLRIS peptide improves targeted docetaxel delivery for prostate cancer: an
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Prostate cancer is one of the most common cancers in the world. Anti-prostate cancer drugs such as docetaxel, doxorubicin, and cabazitaxel have drawbacks resulting from their low solubility, non-targeted transfer, and many side effects. Prostate-specific membrane antigen (PSMA) receptor is expressed on the surface of prostate cancer cells. It was known that "WQPDTAHHWATL" and "GRFLTGGTGRLLRIS" peptides tended to bind this receptor. Theoretical approach: "WQPDTAHHWATL" and "GRFLTGGTGRLLRIS" peptides were attached to the C and N tails of albumin protein, and an engineered albumin was designed. Then, engineered albumin and the extracellular domain of PSMA were separately simulated for 100 ns. Afterward, the interaction of engineered albumin with anti-prostate cancer drugs and the PSMA domain was investigated independently by molecular docking, molecular dynamics simulation, and molecular mechanics energies/Poisson-Boltzmann surface area binding free energy methods. Findings/Results: The binding affinity order of drugs to engineered albumin was docetaxel, doxorubicin, and cabazitaxel, respectively. Also, the residence time of docetaxel was longer than that of other drugs. The final picture of complexes showed that cabazitaxel and docetaxel bound to site IB, and doxorubicin bound to site IIA of the recombinant albumin. Additionally, the C-terminus and N-terminus of the engineered albumin could bind to the PSMA receptor. Conclusion and implications: It can be concluded that this engineered albumin is useful for targeted drug delivery in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.